Nusinersen (Spinraza®) was the first disease-modifying treatment approved by EMA and FDA for SMA patients regardless of their age, SMA type, functional status, and the number of SMN2 gene copies. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.